Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin IV vs Tablet for Postpartum Uterine Contractility
NCT02908126Phase 1Terminated
- Sponsor
- Oxytone Bioscience
- Start
- Apr 2018
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Oxytone Bioscience. Primary endpoint: Uterine contractility: area under the curve (AUC) at 3 hours. Started Apr 2018; status: terminated.
02
Drugs
oxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on NCT02908126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02908126.